文献

J-GLOBAL ID：202102276057797267   整理番号：21A0023570

移植前MRD陰性度は,再発性/難治性急性リンパ芽球性白血病に対する,CAR-T療法の良好な転帰を予測する: 多施設後向き研究【JST・京大機械翻訳】

Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study

著者 (59件)： Zhao Houli (Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China) ,  Zhao Houli (Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China) ,  Zhao Houli (Institute of Hematology, Zhejiang University, Hangzhou, China) ,  Wei Jieping (Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China) ,  Wei Jieping (Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China) ,  Wei Jieping (Institute of Hematology, Zhejiang University, Hangzhou, China) ,  Wei Guoqing (Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China) ,  Wei Guoqing (Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China) ,  Wei Guoqing (Institute of Hematology, Zhejiang University, Hangzhou, China) ,  Luo Yi (Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China) ,  Luo Yi (Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China) ,  Luo Yi (Institute of Hematology, Zhejiang University, Hangzhou, China) ,  Shi Jimin (Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China) ,  Shi Jimin (Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China) ,  Shi Jimin (Institute of Hematology, Zhejiang University, Hangzhou, China) ,  Cui Qu (Department of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China) ,  Zhao Mingfeng (Department of Hematology, Tianjin First Central Hospital, Tianjin, China) ,  Liang Aibin (Department of Hematology, Shanghai Tongji Hospital, Shanghai, China) ,  Zhang Qing (Department of Hematology, Guangdong Second Provincial General Hospital, Guangzhou, China) ,  Yang Jianmin (Department of Hematology, Changhai Hospital of Shanghai, Shanghai, China) ,  Li Xin (Department of Hematology, Xiangya Third Hospital, Changsha, China) ,  Chen Jing (Department of Hematology, Shanghai Children’s Medical Center, Shanghai, China) ,  Song Xianmin (Department of Hematology, Shanghai General Hospital, Shanghai, China) ,  Jing Hongmei (Department of Hematology, Peking University Third Hospital, Beijing, China) ,  Li Yuhua (Department of Hematology, Zhujiang Hospital of Southern Medical University, Guangzhou, China) ,  Hao Siguo (Department of Hematology, Xinhua Hospital of Shanghai, Shanghai, China) ,  Wu Wenjun (Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China) ,  Wu Wenjun (Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China) ,  Wu Wenjun (Institute of Hematology, Zhejiang University, Hangzhou, China) ,  Tan Yamin (Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China) ,  Tan Yamin (Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China) ,  Tan Yamin (Institute of Hematology, Zhejiang University, Hangzhou, China) ,  Yu Jian (Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China) ,  Yu Jian (Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China) ,  Yu Jian (Institute of Hematology, Zhejiang University, Hangzhou, China) ,  Zhao Yanmin (Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China) ,  Zhao Yanmin (Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China) ,  Zhao Yanmin (Institute of Hematology, Zhejiang University, Hangzhou, China) ,  Lai Xiaoyu (Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China) ,  Lai Xiaoyu (Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China) ,  Lai Xiaoyu (Institute of Hematology, Zhejiang University, Hangzhou, China) ,  Yin Elaine Tan Su (Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China) ,  Yin Elaine Tan Su (Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China) ,  Yin Elaine Tan Su (Institute of Hematology, Zhejiang University, Hangzhou, China) ,  Wei Yunxiong (Department of Hematology, Tianjin First Central Hospital, Tianjin, China) ,  Li Ping (Department of Hematology, Shanghai Tongji Hospital, Shanghai, China) ,  Huang Jing (Department of Hematology, Guangdong Second Provincial General Hospital, Guangzhou, China) ,  Wang Tao (Department of Hematology, Changhai Hospital of Shanghai, Shanghai, China) ,  Blaise Didier (Institut Paoli-Calmettes, Marseille, France) ,  Xiao Lei (Innovative Cellular Therapeutics Co, Ltd, Shanghai, China) ,  Chang Alex H. (Shanghai YaKe Biotechnology Ltd, Shanghai, China) ,  Nagler Arnon (Hematology and Bone Marrow Transplantation Division, Chaim Sheba Medical Center, Tel-Hashomer, Israel) ,  Mohty Mohamad (Sorbonne University, Saint-Antoine Hospital, INSERM UMRs 938, Paris, France) ,  Huang He (Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China) ,  Huang He (Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China) ,  Huang He (Institute of Hematology, Zhejiang University, Hangzhou, China) ,  Hu Yongxian (Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China) ,  Hu Yongxian (Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China) ,  Hu Yongxian (Institute of Hematology, Zhejiang University, Hangzhou, China)
資料名： Journal of Hematology & Oncology (Web)  (Journal of Hematology & Oncology (Web))
巻： 13  号： 1  ページ： 1-13  発行年： 2020年 
JST資料番号： U7517A  ISSN： 1756-8722  資料種別： 逐次刊行物 (A)
記事区分： 短報  発行国： イギリス (GBR)  言語： 英語 (EN)

抄録/ポイント： 固形同種造血幹細胞移植は,キメラ抗原受容体T細胞(CAR-T)療法後の再発/難治性急性リンパ芽球性白血病患者に対する議論の余地がある選択肢である。著者らは,患者がCAR-T療法後の半数体造血幹細胞移植から恩恵を受けるかどうかを評価するために多施設後向き研究を行った。CAR-T療法の後の合計122人の患者を登録し,その後の移植(非移植群)のない67人の患者と,その後の半数体造血幹細胞移植(移植群)の55人の患者を含んだ。長期転帰を,ベースライン患者特性とのその関連として評価した。非移植群と比較して,移植レシピエントは,より高い2年全生存率(OS;77.0%対36.4%;P<0.001)および白血病フリー生存(LFS;65.6%対32.8%;P<0.001)を有した。多変量解析は,移植時の最小残留疾患(MRD)陽性が,不良LFS(P=0.005),OS(P=0.035),および再発の高い累積発生率(P=0.045)と関連する独立因子であることを示した。移植前MRD陰性レシピエント(MRD群)は,非移植群(67.2%;P<0.001)および移植前MRD陽性レシピエント(MRD+群)(65.8%;P=0.006)のそれらより,再発(17.3%)の累積発生率が低かった。MRD+および非移植群における再発の累積発生率は,有意に異ならなかった(P=0.139)。非移植,MRD+およびMRD群における2年LFSは,それぞれ32.8%,27.6%および76.1%であった。MRD群は,非移植群(P<0.001)およびMRD+群(P=0.007)より高いLFSを有したが,MRD+および非移植群におけるLFSは,有意に異ならなかった(P=0.305)。MRD群の2年OSは非移植群より高かった(83.3%対36.4%;P<0.001)が,MRD+群のそれとは異ならなかった(83.3%対62.7%;P=0.069)。非移植群とMRD+群のOSは,有意差はなかった(P=0.231)。CAR-T療法後の移植前MRD陰性による造血幹細胞移植は,再発/難治性急性リンパ芽球性白血病患者におけるLFSとOSを大きく改善した。研究は,中国の臨床試験登録(ChiCTR190002357)に登録された。Copyright 2021 The Author(s) All rights reserved. Translated from English into Japanese by JST.【JST・京大機械翻訳】

シソーラス用語： 多変量解析 ,  *白血病 ,  臨床試験 ,  T細胞 ,  半数体 ,  基準線 ,  造血幹細胞移植
準シソーラス用語： *急性リンパ性白血病 ,  *後向き研究 ,  同種造血幹細胞移植 ,  長期予後 ,  移植患者 ,  全生存率 ,  キメラ抗原受容体 , 【Automatic Indexing@JST】

著者キーワード (6件)： キメラ抗原受容体T細胞療法 ,  半数体造血幹細胞移植 ,  白血病のない生存 ,  最小残存疾患陰性度 ,  全生存 ,  再発/難治性急性リンパ芽球性白血病

分類 (2件)： 血液の腫よう  (GK04000M) ,  腫ようの治療一般  (GE03031L)

引用文献 (40件)：

• Blood; Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation; N Gökbuget, D Stanze, J Beck, H Diedrich, HA Horst, A Hüttmann; 120; 2012; 2032-2041; 10.1182/blood-2011-12-399287; citation_id=CR1
• Pediatr Blood Cancer; Hematopoietic stem cell transplantation following unsuccessful salvage treatment for relapsed acute lymphoblastic leukemia in children; J Inagaki, R Fukano, M Noguchi, K Kurauchi, S Tanioka, J Okamura; 62; 2015; 674-679; 10.1002/pbc.25353; citation_id=CR2
• N Engl J Med; Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia; JH Park, I Rivière, M Gonen, X Wang, B Sénéchal, KJ Curran; 378; 2018; 449-459; 10.1056/NEJMoa1709919; citation_id=CR3
• Leukemia; CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia; J Pan, Q Niu, B Deng, S Liu, T Wu, Z Gao; 33; 2019; 2854-2866; 10.1038/s41375-019-0488-7; citation_id=CR4
• Clin Cancer Res; Potent anti-leukemia activities of chimeric antigen receptor-modified T cells against CD19 in Chinese patients with relapsed/refractory acute lymphocytic leukemia; Y Hu, Z Wu, Y Luo, J Shi, J Yu, C Pu; 23; 2017; 3297-3306; 10.1158/1078-0432.CCR-16-1799; citation_id=CR5

タイトルに関連する用語 (8件)： 移植 ,  再発 ,  急性リンパ芽球性白血病 ,  療法 ,  転帰 ,  予測 ,  施設 ,  研究